Status:
TERMINATED
Sleep Apnea in Sickle Cell Disease
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
15-50 years
Phase:
NA
Brief Summary
Despite the fact that obstructive sleep apnoea (OSA) is highly prevalent in the sickle cell population, studies focusing on the associations of the two diseases and their common pathophysiological mec...
Eligibility Criteria
Inclusion
- Homozygous HbS (Hemoglobin S) (SS) patients,
- aged between 15 and 3 months and 50 years old,
- in steady state (i.e. without vaso-occlusive crisis or recent blood transfusion),
- followed by the sickle cell center of the Hospices Civils de Lyon,
- and showing symptoms of OSA.
Exclusion
- Patients receiving treatment of OSA,
- recent blood transfusion (less than 2 months),
- patients not at steady state (VOC or acute chest syndrome less than 2 months),
- pregnancy.
Key Trial Info
Start Date :
May 28 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 29 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03753854
Start Date
May 28 2018
End Date
November 29 2021
Last Update
December 28 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Edouard Herriot
Lyon, France, 69003
2
Centre Léon Berard
Lyon, France, 69008
3
Hôpital de la Croix Rousse
Lyon, France, 69317